<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:cd07ea06-882a-42ac-b003-74942e3109d3,g:85b00dae-0f9c-4f8c-8a93-1090eab14772,d:587880376d744d7298db5d81aa4511c1--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20210629</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV80L2ZyYWc6ZmJiOTc2Y2MwYWIyNGY5ODlhOTI3Y2ZhOTRlNWJhZjYvdGFibGU6NzI4YmEzYzUxYzQ3NGE1YjgzZmU1ZjkwNjgyM2E3ZjMvdGFibGVyYW5nZTo3MjhiYTNjNTFjNDc0YTViODNmZTVmOTA2ODIzYTdmM18yLTEtMS0xLTA_8b553706-03da-4ef6-9874-a68c3bf65cb8">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV80L2ZyYWc6ZmJiOTc2Y2MwYWIyNGY5ODlhOTI3Y2ZhOTRlNWJhZjYvdGFibGU6NzI4YmEzYzUxYzQ3NGE1YjgzZmU1ZjkwNjgyM2E3ZjMvdGFibGVyYW5nZTo3MjhiYTNjNTFjNDc0YTViODNmZTVmOTA2ODIzYTdmM181LTEtMS0xLTA_b6f9694a-1b50-4bb3-8eaf-ef7b578f34c5">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20210629.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-29</xbrli:startDate><xbrli:endDate>2021-06-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i587880376d744d7298db5d81aa4511c1_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTcy_ac562881-1db5-4ac9-b3e5-83954d961333">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNzc_6f901201-52aa-4240-911c-9f9e83b9336f">June 29, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:21.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTc4_2368aa69-782e-4de0-86f2-11a9424e5419">ANGION BIOMEDICA CORP.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8wLTAtMS0xLTA_8a633815-d6ec-4930-9a98-8c9d5944f9b7">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8wLTEtMS0xLTA_c2ea94b1-9fdc-4318-86f3-02e5568d6012">001-39990</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8wLTMtMS0xLTA_dce04071-d866-4e33-a13c-9f7e6190a8a7">11-3430072</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8zLTAtMS0xLTA_23af7e0f-f8df-4c7e-97a1-d23b21e326de">51 Charles Lindbergh Boulevard</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8zLTEtMS0xLTA_30abc6a9-6505-42a4-9b37-9f78146c8b95">Uniondale</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8zLTItMS0xLTA_bdc20d1e-3f76-489d-b692-34fa092445cc">New York</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6YjAyZWQwNTg0NDBkNDQ1MGE2Y2RjMzBmMTM4ZmIzYjgvdGFibGVyYW5nZTpiMDJlZDA1ODQ0MGQ0NDUwYTZjZGMzMGYxMzhmYjNiOF8zLTMtMS0xLTA_cfaf754f-a389-4845-9802-a1ac28eb77e7">11553</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTc0_edee6575-b540-43e8-981e-9d27bbd18cb2">415</ix:nonNumeric>) <ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTc5_543f8397-da37-47e7-9792-c3bde80901ce">655-4899</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTgw_0cfd3b7f-30b7-4d33-acfa-5554f4090dec">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTc1_4114180a-f118-49ef-80aa-d7bd8d48c70c">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTc2_3fea378b-0c2e-444e-a009-db599d12cdbc">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTgx_d2deedae-2352-4fb4-a637-bf090f2178ad">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6MzkzOWE3N2EwNjgzNGY2MmFjMTY3N2RkNjljZmM0ZGIvdGFibGVyYW5nZTozOTM5YTc3YTA2ODM0ZjYyYWMxNjc3ZGQ2OWNmYzRkYl8xLTAtMS0xLTA_05439edf-be89-426c-b081-f317c8b8a037">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6MzkzOWE3N2EwNjgzNGY2MmFjMTY3N2RkNjljZmM0ZGIvdGFibGVyYW5nZTozOTM5YTc3YTA2ODM0ZjYyYWMxNjc3ZGQ2OWNmYzRkYl8xLTEtMS0xLTA_8797b13d-0f98-49fd-8b4e-f7e014ab4c03">ANGN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGFibGU6MzkzOWE3N2EwNjgzNGY2MmFjMTY3N2RkNjljZmM0ZGIvdGFibGVyYW5nZTozOTM5YTc3YTA2ODM0ZjYyYWMxNjc3ZGQ2OWNmYzRkYl8xLTItMS0xLTA_df7618cc-3d48-4ee3-9ec9-e0ba8de37818">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xMzEx_0b1d994e-e61b-4bd3-8ddf-00f21370f570">&#9746;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe3c9aa5d2c9415a9b08ed068f373961_D20210629-20210629" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjU4Nzg4MDM3NmQ3NDRkNzI5OGRiNWQ4MWFhNDUxMWMxL3NlYzo1ODc4ODAzNzZkNzQ0ZDcyOThkYjVkODFhYTQ1MTFjMV8xL2ZyYWc6MmIwYTU3ODU1M2U0NGI1NWE3YWJhZjJmNjVkMTZhZWMvdGV4dHJlZ2lvbjoyYjBhNTc4NTUzZTQ0YjU1YTdhYmFmMmY2NWQxNmFlY18xNTgz_e89c477d-8cfe-4d6f-a310-59044ba8de92">o</ix:nonNumeric></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i587880376d744d7298db5d81aa4511c1_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 Other Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Angion Biomedica Corp. (&#8220;Angion&#8221; or the &#8220;Company&#8221;) announced its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet its primary or secondary efficacy endpoints. The adverse events and overall safety of the trial was consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.  A total of 120 patients were randomized 1:1 in the trial, with 59 patients in the active treatment arm and 61 patients in the standard of care arm. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any statements contained in this Form 8-K regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company&#8217;s expectations regarding ANG-3777. The Company&#8217;s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. You should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i587880376d744d7298db5d81aa4511c1_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ JAY R. VENKATESAN, M.D.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date: June 29, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer and Director</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "angn-20210629.htm", "description": "8-K", "secsgml_size_bytes": 33595}]
{"company-data": {"conformed-name": "Angion Biomedica Corp.", "cik": "0001601485", "assigned-sic": "2834", "irs-number": "113430072", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39990", "film-number": "211058199"}, "business-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553", "phone": "(415) 655-4899"}, "mail-address": {"street1": "51 CHARLES LINDBERGH BOULEVARD", "city": "UNIONDALE", "state": "NY", "zip": "11553"}}
angn-20210629
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
June 29, 2021
Date of Report (date of earliest event reported)
ANGION BIOMEDICA CORP.
(Exact name of registrant as specified in its charter)
Delaware
001-39990
11-3430072
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
51 Charles Lindbergh Boulevard
Uniondale
New York
11553
(Address of Principal Executive Offices)
(Zip Code)
(
415
)
655-4899
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
ANGN
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 8.01 Other Events
On June 29, 2021, Angion Biomedica Corp. ("Angion" or the "Company") announced its exploratory Phase 2 ALI-201 trial of ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS) did not meet its primary or secondary efficacy endpoints. The adverse events and overall safety of the trial was consistent with previously published reports in patients hospitalized with severe COVID-19 pneumonia.  A total of 120 patients were randomized 1:1 in the trial, with 59 patients in the active treatment arm and 61 patients in the standard of care arm.
Forward-Looking Statements
Any statements contained in this Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company's expectations regarding ANG-3777. The Company's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time. You should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ANGION BIOMEDICA CORP.
By:
/s/ JAY R. VENKATESAN, M.D.
Date: June 29, 2021
Jay R. Venkatesan, M.D.
President and Chief Executive Officer and Director